Back to Authors

Comfere, Nneka I.

https://orcid.org/0000-0002-8001-2639

Mayo Clinic

Mayo Clinic

Citations 62

Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
Wada, David A., Ziesmer, Steven C., Elsawa, Sherine F. , Comfere, Nneka I. , Dietz, Allan B. , Novak, Anne J. , Feldman, Andrew L. , Pittelkow, Mark R. , Ansell, Stephen M. , Wilcox, Ryan A. , Witzig, Thomas E. , Feldman, Andrew L , Elsawa, Sherine F , Dietz, Allan B

Blood | August 12, 2009 | Volume: 114 | Issue: 14 | Pages: 2936-2944

10.1182/blood-2009-05-220111 Get It

A variety of nonmalignant cells present in the tumor microenvironment promotes tumorigenesis by stimulating tumor cell growth and metastasis or suppressing host immunity. The role of such stromal cells in T-cell lymphoproliferative disorders is incompletely understood. Monocyte-derived cells (MDCs), including professional antigen-presenting cells such as dendritic cells (DCs), play a central role in T-cell biology. Here, we provide evidence that monocytes promote the survival of malignant T cells and demonstrate that MDCs are abundant within the tumor microenvironment of T cell–derived lymphomas. Malignant T cells were observed to remain viable during in vitro culture with autologous monocytes, but cell death was significantly increased after monocyte depletion. Furthermore, monocytes prevent the induction of cell death in T-cell lymphoma lines in response to either serum starvation or doxorubicin, and promote the engraftment of these cells in nonobese diabetic/severe combined immunodeficient mice. Monocytes are actively recruited to the tumor microenvironment by CCL5 (RANTES), where their differentiation into mature DCs is impaired by tumor-derived interleukin-10. Collectively, the data presented demonstrate a previously undescribed role for monocytes in T-cell lymphoproliferative disorders.
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Feldman, Andrew L. , Wada, David A., Yang, Zhi‐Zhang, Comfere, Nneka I. , Dong, Haidong , Kwon, Eugene D., Novak, Anne J. , Pittelkow, Mark R. , Ansell, Stephen M. , Wilcox, Ryan A. , Markovic, Svetomir N. , Witzig, Thomas E. , Feldman, Andrew L , Dong, Haidong

Blood | July 14, 2009 | Volume: 114 | Issue: 10 | Pages: 2149-2158

10.1182/blood-2009-04-216671 Get It

AbstractStromal elements present within the tumor microenvironment may suppress host immunity and promote the growth of malignant lymphocytes in B cell–derived non-Hodgkin lymphoma (NHL). In contrast, little is known about the microenvironment's role in T cell–derived NHL. B7-H1 (PD-L1, CD274), a member of the B7 family of costimulatory/coinhibitory ligands expressed by both malignant cells and stromal cells within the tumor microenvironment, has emerged as an important immune modulator capable of suppressing host immunity. Therefore, B7-H1 expression and function were analyzed in cutaneous and peripheral T-cell NHL. B7-H1 was expressed by tumor cells, monocytes, and monocyte-derived cells within the tumor microenvironment in T-cell NHL and was found to inhibit T-cell proliferation and promote the induction of FoxP3+ regulatory T cells. Collectively, the data presented provide the first evidence implicating B7-H1 in the suppression of host immunity in T-cell lymphoproliferative disorders and suggest that the targeting of B7-H1 may represent a novel therapeutic approach.